RevMed's Pancreatic Cancer Pill Priced Above $475K per Year
BloombergDuration: 10:08
Read the full storyUp next
- Angelini CEO Marullo di Condojanni on M&A Prospects
- Delta Demand Looks Good Despite Fuel Prices, Jeffries Analyst Says
- Iran, Middle East Stirring Up Ahead of Midterms, Says BI's Sanders
- Money Doesn't Want to Leave Equities, Says Baird Strategas' Verrone
- Delta Cites Higher Fuel Prices in Reducing Profit Outlook
- 'Medieval' US Firing-Squad Execution Will Hurt Republicans in Midterms: Reid
